MedTrace Logo

Convalescent Plasma Therapy for COVID-19 Patients

NCT04565197 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-12-08

No results posted yet for this study

Summary

Passive immunization involves the administration of antibodies against a given agent to a susceptible individual for the purpose of preventing or treating an infectious disease due to that agent. A general principle of passive antibody therapy is that it is more effective when used for prophylaxis than for treatment of disease. When used for therapy, antibody is most effective when administered shortly after the onset of symptoms

Conditions

  • SARS-CoV Infection

Interventions

BIOLOGICAL

convalescent plasma

Transfuse 2 aliquots of plasma (200 mL x 2) per patient. * Transfuse first aliquot for 2-3 hours (\~1.4 to 2 mL/min) * Transfuse second aliquot at same rate 2 hours after completion of first aliquot

Sponsors & Collaborators

  • Lahore General Hospital

    lead OTHER_GOV

Principal Investigators

  • Muhammad Irfan Malik, FCPS · Post-Graduate Medical Institute, Lahore General Hospital, Lahore Pakistan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2020-12-30
Completion
2020-12-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04565197 on ClinicalTrials.gov